{"disease":{"id":"transthyretin-amyloidosis","name":"transthyretin amyloidosis"},"drugs":{"marketed":[{"drug_id":"tafamidis","indication_name":"Wild-type transthyretin cardiac amyloidosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vyndaqel","generic_name":"tafamidis","company_name":"Foldrx Pharms","drug_phase":"marketed","molecular_target":"Transthyretin","drug_class":"tafamidis","quality_score":10,"revenue":"1430.0","mechanism":"Vyndaqel works by stabilizing the transthyretin protein to prevent its misfolding and aggregation into amyloid fibrils."},{"drug_id":"vyndaqel","indication_name":"Wild-type transthyretin cardiac amyloidosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vyndaqel","generic_name":"Tafamidis Meglumine","company_name":"Foldrx Pharms","drug_phase":"marketed","molecular_target":"Transthyretin (TTR)","drug_class":"Transthyretin stabilizer","quality_score":10,"revenue":null,"mechanism":"Tafamidis selectively stabilizes TTR tetramer by binding at thyroxine sites, slowing monomer dissociation."},{"drug_id":"eplontersen","indication_name":"Polyneuropathy of hereditary transthyretin-mediated amyloidosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Wainua","generic_name":"EPLONTERSEN","company_name":"Astrazeneca Ab","drug_phase":"marketed","molecular_target":"","drug_class":"Transthyretin-directed RNA Interaction [EPC]","quality_score":10,"revenue":null,"mechanism":"Wainua works by binding to the transthyretin RNA to prevent the production of the transthyretin protein."},{"drug_id":"acoramidis","indication_name":"cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Attruby","generic_name":"ACORAMIDIS","company_name":"Bridgebio Pharma","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":53,"revenue":null,"mechanism":"Attruby works by stabilizing the transthyretin protein to prevent its misfolding and aggregation into amyloid fibrils."},{"drug_id":"vyndamax","indication_name":"Wild-type transthyretin cardiac amyloidosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vyndaqel","generic_name":"Tafamidis","company_name":"Foldrx Pharms","drug_phase":"marketed","molecular_target":"Transthyretin","drug_class":"tafamidis","quality_score":10,"revenue":null,"mechanism":"Vyndaqel stabilizes the Transthyretin protein, preventing its misfolding and aggregation into amyloid fibrils."},{"drug_id":"eplontersen","indication_name":"polyneuropathy of hereditary transthyretin-mediated amyloidosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Wainua","generic_name":"EPLONTERSEN","company_name":"Astrazeneca Ab","drug_phase":"marketed","molecular_target":"","drug_class":"Transthyretin-directed RNA Interaction [EPC]","quality_score":10,"revenue":null,"mechanism":"Wainua works by binding to the transthyretin RNA to prevent the production of the transthyretin protein."},{"drug_id":"tafamidis-test","indication_name":"Wild-type transthyretin cardiac amyloidosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vyndaqel","generic_name":"tafamidis-test","company_name":"Foldrx Pharms","drug_phase":"marketed","molecular_target":"Transthyretin","drug_class":"tafamidis","quality_score":10,"revenue":null,"mechanism":"Vyndaqel works by stabilizing the transthyretin protein to prevent its misfolding and aggregation into amyloid fibrils."}],"pipeline":[],"offLabel":[],"totalMarketed":7,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06328075","title":"Artificial Intelligence to Assist the Echocardiographic Identification of Transthyretin Cardiac Amyloidosis","phase":"","overall_status":"UNKNOWN","enrollment_count":15000,"lead_sponsor_name":"Algalarrondo Vincent","has_results":false},{"nct_id":"NCT00628745","title":"Transthyretin Amyloidosis Outcome Survey (THAOS)","phase":"","overall_status":"COMPLETED","enrollment_count":6718,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT03237494","title":"TRAMmoniTTR Study Genetic Screening of an At-risk Population for hATTR and Monitoring of TTR Positive Subjects","phase":"","overall_status":"COMPLETED","enrollment_count":5028,"lead_sponsor_name":"CENTOGENE GmbH Rostock","has_results":false},{"nct_id":"NCT07358078","title":"DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Alnylam Pharmaceuticals","has_results":false},{"nct_id":"NCT06465810","title":"Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis","phase":"","overall_status":"RECRUITING","enrollment_count":1850,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT06338839","title":"Transthyretin Amyloidosis Cardiomyopathy in Patients With HFpEF in Russia","phase":"","overall_status":"TERMINATED","enrollment_count":1770,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT04561518","title":"ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)","phase":"","overall_status":"RECRUITING","enrollment_count":1500,"lead_sponsor_name":"Alnylam Pharmaceuticals","has_results":false},{"nct_id":"NCT07052903","title":"TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1250,"lead_sponsor_name":"Alnylam Pharmaceuticals","has_results":false},{"nct_id":"NCT05772091","title":"Prognostic Value of Echocardiographic Parameters Based on Machine Learning Approach","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"Pr. Nicolas GIRERD","has_results":false},{"nct_id":"NCT03842163","title":"Prevalence and Characteristics of Transthyretin Amyloidosis in Patients With Left Ventricular Hypertrophy of Unknown Etiology","phase":"","overall_status":"COMPLETED","enrollment_count":812,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT07238426","title":"ATTRACT-52: Primary Care Cardiac Amyloidosis Screening in Ordu, Turkey","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":800,"lead_sponsor_name":"Kotyora Family Medicine Health Management and Education Association","has_results":false},{"nct_id":"NCT06414746","title":"Hereditary Transthyretin Amyloidosis Polyneuropathy in Patients With Carpal Tunnel Syndrome in Russia","phase":"","overall_status":"COMPLETED","enrollment_count":721,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT06679946","title":"A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy","phase":"PHASE3","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":700,"lead_sponsor_name":"Alnylam Pharmaceuticals","has_results":false},{"nct_id":"NCT04153149","title":"HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":655,"lead_sponsor_name":"Alnylam Pharmaceuticals","has_results":true},{"nct_id":"NCT03860935","title":"Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":632,"lead_sponsor_name":"Eidos Therapeutics, a BridgeBio company","has_results":true},{"nct_id":"NCT05064839","title":"Imaging for the Evaluation of Transthyretin Cardiac Amyloidosis Prevalence of Patients Over 65 Hospitalized in Cardiology Wards (the IMPACT Study)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":553,"lead_sponsor_name":"Poitiers University Hospital","has_results":false},{"nct_id":"NCT05577819","title":"Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF","phase":"NA","overall_status":"RECRUITING","enrollment_count":515,"lead_sponsor_name":"Massachusetts General Hospital","has_results":false},{"nct_id":"NCT03190577","title":"Assessment of the Prevalence of TTR Amyloid Neuropathy in a Population of Patients With Neuropathy of Unknown Aetiology","phase":"NA","overall_status":"COMPLETED","enrollment_count":400,"lead_sponsor_name":"Nantes University Hospital","has_results":false},{"nct_id":"NCT03997383","title":"APOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":360,"lead_sponsor_name":"Alnylam Pharmaceuticals","has_results":true},{"nct_id":"NCT04563286","title":"Patient-Reported Outcome Measures in Wild-Type and Variant Cardiac Transthyretin Amyloidosis","phase":"","overall_status":"UNKNOWN","enrollment_count":250,"lead_sponsor_name":"University of Messina","has_results":false},{"nct_id":"NCT04850105","title":"A Non-interventional Cohort Safety Study of Patients With hATTR-PN","phase":"","overall_status":"RECRUITING","enrollment_count":240,"lead_sponsor_name":"Akcea Therapeutics","has_results":false},{"nct_id":"NCT07306949","title":"Real-Life Clinical Efficacy of Acoramidis in Participants With ATTR-CM and Association With Cardiac Biomarkers","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT03923920","title":"Screening for Systemic Amyloidosis Via the Ligamentum Flavum","phase":"","overall_status":"COMPLETED","enrollment_count":200,"lead_sponsor_name":"The Cleveland Clinic","has_results":false},{"nct_id":"NCT01737398","title":"Efficacy and Safety of Inotersen in Familial Amyloid Polyneuropathy","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":173,"lead_sponsor_name":"Ionis Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT03759379","title":"HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":164,"lead_sponsor_name":"Alnylam Pharmaceuticals","has_results":true},{"nct_id":"NCT06907186","title":"An Interventional Pilot Study to Investigate the Feasibility and Acceptance of a Structured Psychological Support Program for Patients, Caregivers, and Presymptomatic Carriers in Hereditary Transthyretin Amyloidosis With Cardiomyopathy","phase":"NA","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"Fondazione IRCCS Policlinico San Matteo di Pavia","has_results":false},{"nct_id":"NCT05758493","title":"Characterizing Iodine-124 Evuzumitide (AT-01) in Systemic Amyloidosis","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"Oregon Health and Science University","has_results":false},{"nct_id":"NCT02175004","title":"Extension Study Assessing Long Term Safety and Efficacy of IONIS-TTR Rx in Familial Amyloid Polyneuropathy (FAP)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":135,"lead_sponsor_name":"Ionis Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT04513600","title":"ATTR-Cardiomyopathy Stabilization Following Tafamidis Therapy","phase":"","overall_status":"UNKNOWN","enrollment_count":131,"lead_sponsor_name":"The Christ Hospital","has_results":false},{"nct_id":"NCT07223203","title":"TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":125,"lead_sponsor_name":"Alnylam Pharmaceuticals","has_results":false},{"nct_id":"NCT04276220","title":"Prevalence of wtATTR-CM After Carpal Tunnel Release Surgery","phase":"NA","overall_status":"COMPLETED","enrollment_count":109,"lead_sponsor_name":"Steen Hvitfeldt Poulsen","has_results":false},{"nct_id":"NCT03886155","title":"Cardiac Amyloidosis Screening at Trigger Finger Release","phase":"","overall_status":"COMPLETED","enrollment_count":107,"lead_sponsor_name":"The Cleveland Clinic","has_results":false},{"nct_id":"NCT05814380","title":"The Regional Scintigraphic DPD Uptake in Cardiac Transthyretin Amyloidosis.","phase":"","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Katarzyna Holcman","has_results":false},{"nct_id":"NCT05409833","title":"Systemic Transthyretin Amyloidosis: Carpal Tunnel Syndrome in a Portuguese Population","phase":"","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Universidade do Porto","has_results":false},{"nct_id":"NCT06365593","title":"hATTR Polyneuropathy in Russia","phase":"","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT06345235","title":"New Biomarkers and Plasma Prothrombotic Potential in Cardiac Transthyretin Amyloidosis","phase":"","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"John Paul II Hospital, Krakow","has_results":false},{"nct_id":"NCT05661916","title":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALN-TTRSC04 in Healthy Subjects","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":96,"lead_sponsor_name":"Alnylam Pharmaceuticals","has_results":false},{"nct_id":"NCT03966105","title":"Prevalence of Wild Type ATTR","phase":"","overall_status":"COMPLETED","enrollment_count":94,"lead_sponsor_name":"Oncology Institute of Southern Switzerland","has_results":false},{"nct_id":"NCT05929209","title":"Exploring Biomarkers in Hereditary Transthyretin Amyloidosis","phase":"NA","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT02797847","title":"A Safety and Tolerability Study of an Investigational Drug, ALN-TTRSC02, in Healthy Subjects","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":80,"lead_sponsor_name":"Alnylam Pharmaceuticals","has_results":false},{"nct_id":"NCT04601051","title":"Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-2001 in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy (ATTRv-PN) and Patients With Transthyretin Amyloidosis-Related Cardiomyopathy (ATTR-CM)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":72,"lead_sponsor_name":"Intellia Therapeutics","has_results":false},{"nct_id":"NCT07080268","title":"Validation of a Questionnaire for Quality of Life Assessment in Patients With Transthyretin Amyloidosis.","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":70,"lead_sponsor_name":"Hospital General de Niños Pedro de Elizalde","has_results":false},{"nct_id":"NCT04201418","title":"A Multicenter Observational Study to Evaluate the Effectiveness of Patisiran in Patients With Polyneuropathy of ATTRv Amyloidosis With a V122I or T60A Mutation","phase":"","overall_status":"COMPLETED","enrollment_count":67,"lead_sponsor_name":"Alnylam Pharmaceuticals","has_results":false},{"nct_id":"NCT03588468","title":"Expanding the Biomarkers in Familial Amyloid Neuropathy: MRI and Motor Unit Estimation by Electrophysiological Study","phase":"NA","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Assistance Publique Hopitaux De Marseille","has_results":false},{"nct_id":"NCT06921408","title":"Retrospective Identification of Scintigraphic Cardiac Amyloidosis (RISCA)","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":57,"lead_sponsor_name":"University Hospital, Lille","has_results":false},{"nct_id":"NCT06393465","title":"Real-World Effectiveness of High-Dose Tafamidis on Neurologic Disease Progression in Mixed-Phenotype Transthyretin Amyloid Cardiomyopathy","phase":"","overall_status":"COMPLETED","enrollment_count":50,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT05797857","title":"Exercise Training in Transthyretin Cardiac Amyloidosis","phase":"NA","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT03431896","title":"Monitoring of Early Disease Progression in Hereditary Transthyretin Amyloidosis","phase":"","overall_status":"COMPLETED","enrollment_count":37,"lead_sponsor_name":"The Cleveland Clinic","has_results":false},{"nct_id":"NCT05075798","title":"Study of Cerebral MRI Anomalies in Mutated Transthyretin Amyloidosis Patients","phase":"","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"Centre Hospitalier Universitaire de Nīmes","has_results":false},{"nct_id":"NCT06539208","title":"A Phase I/IIa，Open-label, Single Ascending Dose and Dose-expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of YOLT-201 in Patients With Transthyretin Amyloidosis Polyneuropathy (ATTR-PN) or Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":31,"lead_sponsor_name":"YolTech Therapeutics Co., Ltd","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}